Biotech Values

[mskatiescarletohara]

Dew----ADH

++++will now be limited to NSCLC and ovarian cancer

According to guidance I recieved from the company last year, the objective in this trial was to determine which tumor type responds favorably to ADH-1 after repeat dosing. I feel fairly confident in assuming tumor response was noted in these two indications thus the plan to move forward with the weekly dosing schedule in these tumor types.

++++ U.S. phase-2 combination trial with chemotherapy is expected to start soon. The NCI is planning to run additional U.S. trials

I anxiously await the NCI pre-clinical data supporting the above trial.


ADH IMHO, certainly qualifies as a Biotech Value! C'mon GSK step up to the plate!!! Going fishing today and tomorrow!


katie.....